Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00603447 | Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma | completed | Phase 1 | 84 | AmgenINDUSTRY | 2 | May 30, 2017 | clinicaltrials |
| NCT00811733 | A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia | completed | Phase 2 | 37 | GlaxoSmithKlineINDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT01980589 |
| A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects(CHAMPION 2) |
| completed |
| Phase 1 |
| 22 |
| AmgenINDUSTRY |
| 1 |
| May 30, 2017 |
| clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01582295 | XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease | completed | Phase 1 | 4 | Massachusetts General HospitalOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01234467 | Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | completed | Phase 2 | 23 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01432600 | Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide | completed | Phase 1 / Phase 2 | 80 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT03057418 | Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim | completed | Phase 1 | 7 | Biointegrator LLCINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT00244855 | Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma | completed | Phase 2 | 32 | Fred Hutchinson Cancer CenterOTHER | 1 | May 22, 2017 | clinicaltrials |
| NCT01313897 | UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma(NK2010-35) | completed | Phase 2 | 10 | University of ArkansasOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00619684 | Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant | completed | Phase 2 | 18 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT00642395 | Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) | completed | Phase 2 | 61 | University Hospital, ToulouseOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT01206205 | Frontline Therapy in de Novo Multiple Myeloma Patients Under 65(IFM2008) | completed | Phase 2 | 31 | University Hospital, ToulouseOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT02260414 | Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer(METRO B) | completed | Phase 2 | 19 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | May 11, 2017 | clinicaltrials |
| NCT03147326 | Diagnostic Imaging of Myeloma Bone Lesions(RAMP) | completed | N/A | 14 | Herlev HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01056276 | Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy | completed | Phase 2 | 59 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00150462 | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | completed | Phase 1 | 48 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT00530816 | Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma | completed | Phase 2 | 164 | AmgenINDUSTRY | 2 | May 2, 2017 | clinicaltrials |
| NCT01302392 | A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma(FOCUS) | completed | Phase 3 | 315 | AmgenINDUSTRY | 19 | May 2, 2017 | clinicaltrials |
| NCT01949532 | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease | completed | Phase 1 | 26 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT02072863 | A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 9 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT01226849 | Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma(SGH652) | completed | Phase 1 | 6 | Singapore General HospitalOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT01194791 | Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed(LENDEXAL) | completed | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02708732 | Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL) | completed | — | 91 | Hoffmann-La RocheINDUSTRY | 1 | Apr 20, 2017 | clinicaltrials |
| NCT01884688 | UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma | completed | Phase 2 | 3 | University of ArkansasOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01351623 | Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 44 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT00446342 | Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | completed | Phase 1 | 21 | Sunesis PharmaceuticalsINDUSTRY | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01004991 | Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma | completed | Phase 1 / Phase 2 | 14 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT00097981 | A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 225 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00636909 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders(MINI HEME) | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 0 | Apr 6, 2017 | clinicaltrials |
| NCT01323751 | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma(ACY-1215) | completed | Phase 1 / Phase 2 | 120 | CelgeneINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01929720 | Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors(FOCUS) | completed | N/A | 33 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00005988 | Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy | completed | Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00732641 | Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) | completed | Phase 3 | 244 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 4, 2017 | clinicaltrials |
| NCT03087929 | Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon | completed | — | 12 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT00890552 | A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis | completed | N/A | 25 | Stanford UniversityOTHER | 1 | Mar 22, 2017 | clinicaltrials |
| NCT01626547 | Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology | completed | — | 291 | Hospira, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT02129569 | Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers | completed | N/A | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01955395 | Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma | completed | N/A | 93 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT00259740 | Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab | completed | Phase 2 | 96 | AmgenINDUSTRY | 0 | Mar 15, 2017 | clinicaltrials |
| NCT00140582 | Primary Rituximab and Maintenance | completed | Phase 3 | 1,217 | Lymphoma Study AssociationOTHER | 12 | Mar 13, 2017 | clinicaltrials |
| NCT00577642 | Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates | completed | Phase 2 | 29 | Massachusetts General HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT01277016 | A Trial for Systemic Light-chain (AL) Amyloidosis(EMN-03) | completed | Phase 3 | 110 | European Myeloma Network B.V.NETWORK | 1 | Mar 10, 2017 | clinicaltrials |
Data updated 23 days agoSource updated May 30, 2017source: clinicaltrials